# Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.

> **NCT00148551** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Canadian Retinal Trials Group** · enrollment: 120 (estimated)

## Conditions studied

- Age-Related Macular Degeneration

## Interventions

- **DRUG:** Triamcinolone Acetonide

## Key facts

- **NCT ID:** NCT00148551
- **Lead sponsor:** Canadian Retinal Trials Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2008-03
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2007-07-30

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00148551

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00148551, "Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00148551. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*